<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32106710</PMID><DateCompleted><Year>2021</Year><Month>06</Month><Day>09</Day></DateCompleted><DateRevised><Year>2021</Year><Month>06</Month><Day>09</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2167-9223</ISSN><JournalIssue CitedMedium="Internet"><Volume>21</Volume><Issue>3-4</Issue><PubDate><Year>2020</Year><Month>May</Month></PubDate></JournalIssue><Title>Amyotrophic lateral sclerosis &amp; frontotemporal degeneration</Title><ISOAbbreviation>Amyotroph Lateral Scler Frontotemporal Degener</ISOAbbreviation></Journal><ArticleTitle>A comprehensive serum lipidome profiling of amyotrophic lateral sclerosis.</ArticleTitle><Pagination><StartPage>252</StartPage><EndPage>262</EndPage><MedlinePgn>252-262</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1080/21678421.2020.1730904</ELocationID><Abstract><AbstractText><i>Objective</i>: To perform a comprehensive lipid profiling to evaluate potential lipid metabolic differences between patients with amyotrophic lateral sclerosis (ALS) and controls, and to provide a more profound understanding of the metabolic abnormalities in ALS. <i>Methods</i>: Twenty patients with ALS and 20 healthy controls were enrolled in a cross-sectional study. Untargeted lipidomics profiling in fasting serum samples were performed by optimized UPLC-MS platforms for broad lipidome coverage. Datasets were analyzed by univariate and a variety of multivariate procedures. <i>Results</i>: We provide the most comprehensive blood lipid profiling of ALS to date, with a total of 416 lipids measured. Univariate analysis showed that 28 individual lipid features and two lipid classes, triacylglycerides and oxidized fatty acids (FAs), were altered in patients with ALS, although none of these changes remained significant after multiple comparison adjustment. Most of these changes remained constant after removing from the analysis individuals treated with lipid-lowering drugs. The non-supervised principal component analysis did not identify any lipid clustering of patients with ALS and controls. Despite this, we performed a variety of linear and non-linear supervised multivariate models to select the most reliable features that discriminate the lipid profile of patients with ALS from controls. These were the monounsaturated FAs C24:1n-9 and C14:1, the triglyceride TG(51:4) and the sphingomyelin SM(36:2). <i>Conclusions</i>: Peripheral alterations of lipid metabolism are poorly defined in ALS, triacylglycerides and certain types of FAs could contribute to the different lipid profile of patients with ALS. These findings should be validated in an independent cohort.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Fern&#xc1;ndez-Eulate</LastName><ForeName>Gorka</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Neurology Department, Donostia University Hospital, San Sebasti&#xe1;n, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurosciences, Biodonostia Health Research Institute, San Sebasti&#xe1;n, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ruiz-Sanz</LastName><ForeName>Jos&#xc9; Ignacio</ForeName><Initials>JI</Initials><AffiliationInfo><Affiliation>Physiology Department, Medicine and Nursing School, University of the Basque Country UPV/EHU, Lejona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Riancho</LastName><ForeName>Javier</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Neurology Department, Sierrallana Hospital, Torrelavega, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>CIBERNED (Network Center for Biomedical Research in Neurodegenerative Diseases), Carlos III Institute of Health, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zufir&#xcd;a</LastName><ForeName>Monica</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neurosciences, Biodonostia Health Research Institute, San Sebasti&#xe1;n, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>CIBERNED (Network Center for Biomedical Research in Neurodegenerative Diseases), Carlos III Institute of Health, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gere&#xd1;u</LastName><ForeName>Gorka</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Neurosciences, Biodonostia Health Research Institute, San Sebasti&#xe1;n, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>CIBERNED (Network Center for Biomedical Research in Neurodegenerative Diseases), Carlos III Institute of Health, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fern&#xc1;ndez-Torr&#xd3;n</LastName><ForeName>Roberto</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Neurology Department, Donostia University Hospital, San Sebasti&#xe1;n, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurosciences, Biodonostia Health Research Institute, San Sebasti&#xe1;n, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Poza-Aldea</LastName><ForeName>Juan Jos&#xc9;</ForeName><Initials>JJ</Initials><AffiliationInfo><Affiliation>Neurology Department, Donostia University Hospital, San Sebasti&#xe1;n, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ondaro</LastName><ForeName>Jon</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Neurosciences, Biodonostia Health Research Institute, San Sebasti&#xe1;n, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>CIBERNED (Network Center for Biomedical Research in Neurodegenerative Diseases), Carlos III Institute of Health, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Espinal</LastName><ForeName>Juan Bautista</ForeName><Initials>JB</Initials><AffiliationInfo><Affiliation>Neurology Department, Donostia University Hospital, San Sebasti&#xe1;n, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gonz&#xc1;lez-Chinch&#xd3;n</LastName><ForeName>Gonzalo</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Neurology Department, Araba University Hospital, Vitoria-Gasteiz, Spain, and.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zulaica</LastName><ForeName>Miren</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neurosciences, Biodonostia Health Research Institute, San Sebasti&#xe1;n, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>CIBERNED (Network Center for Biomedical Research in Neurodegenerative Diseases), Carlos III Institute of Health, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ruiz-Larrea</LastName><ForeName>Maria Bego&#xd1;a</ForeName><Initials>MB</Initials><AffiliationInfo><Affiliation>Physiology Department, Medicine and Nursing School, University of the Basque Country UPV/EHU, Lejona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>L&#xd3;pez De Munain</LastName><ForeName>Adolfo</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Neurology Department, Donostia University Hospital, San Sebasti&#xe1;n, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurosciences, Biodonostia Health Research Institute, San Sebasti&#xe1;n, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>CIBERNED (Network Center for Biomedical Research in Neurodegenerative Diseases), Carlos III Institute of Health, Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neurosciences Department, Medicine and Nursing School, University of the Basque Country UPV/EHU, San Sebastian, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gil-Bea</LastName><ForeName>Francisco Javier</ForeName><Initials>FJ</Initials><AffiliationInfo><Affiliation>Department of Neurosciences, Biodonostia Health Research Institute, San Sebasti&#xe1;n, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>CIBERNED (Network Center for Biomedical Research in Neurodegenerative Diseases), Carlos III Institute of Health, Madrid, Spain.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>02</Month><Day>28</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Amyotroph Lateral Scler Frontotemporal Degener</MedlineTA><NlmUniqueID>101587185</NlmUniqueID><ISSNLinking>2167-8421</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002851" MajorTopicYN="N">Chromatography, High Pressure Liquid</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000081362" MajorTopicYN="N">Lipidomics</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053719" MajorTopicYN="N">Tandem Mass Spectrometry</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">ALS</Keyword><Keyword MajorTopicYN="N">lipidome</Keyword><Keyword MajorTopicYN="N">lipidomics</Keyword><Keyword MajorTopicYN="N">serum</Keyword><Keyword MajorTopicYN="N">triacylglycerides</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>2</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>6</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>2</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32106710</ArticleId><ArticleId IdType="doi">10.1080/21678421.2020.1730904</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>